Amgen (NASDAQ: AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE